BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Narváez J, Robles-pérez A, Molina-molina M, Vicens-zygmunt V, Luburich P, Yañez MA, Alegre JJ, Nolla JM. Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease. Seminars in Arthritis and Rheumatism 2020;50:902-10. [DOI: 10.1016/j.semarthrit.2020.08.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Li L. Rituximab for connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Int J Rheum Dis 2023;26:225-35. [PMID: 36378118 DOI: 10.1111/1756-185X.14495] [Reference Citation Analysis]
2 Xu L, Wang F, Luo F. Rituximab for the treatment of connective tissue disease–associated interstitial lung disease: A systematic review and meta-analysis. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1019915] [Reference Citation Analysis]
3 Narváez J, Díaz del Campo Fontecha P, Brito García N, Bonilla G, Aburto M, Castellví I, Cano-jiménez E, Mena-vázquez N, Nieto MA, Ortiz AM, Valenzuela C, Abad Hernández MÁ, Castrejón I, Correyero Plaza M, Francisco Hernández FM, Hernández Hernández MV, Rodríquez Portal JA. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment. Reumatología Clínica (English Edition) 2022. [DOI: 10.1016/j.reumae.2022.03.004] [Reference Citation Analysis]
4 Molina-Molina M, Castellví I, Valenzuela C, Ramirez J, Rodríguez Portal JA, Franquet T, Narváez J. Management of progressive pulmonary fibrosis associated with connective tissue disease. Expert Rev Respir Med 2022. [PMID: 35912842 DOI: 10.1080/17476348.2022.2107508] [Reference Citation Analysis]
5 Liossis SC, Bounia CA. Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion. Front Med 2022;9:937561. [DOI: 10.3389/fmed.2022.937561] [Reference Citation Analysis]
6 Mena-vázquez N, Rojas-gimenez M, Fuego-varela C, García-studer A, Perez-gómez N, Romero-barco CM, Godoy-navarrete FJ, Manrique-arija S, Gandía-martínez M, Calvo-gutiérrez J, Morales-garrido P, Mouriño-rodriguez C, Castro-pérez P, Añón-oñate I, Espildora F, Aguilar-hurtado MC, Hidalgo Conde A, Arnedo Díez de los Ríos R, Cabrera César E, Redondo-rodriguez R, Velloso-feijoo ML, Fernández-nebro A. Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease. Biomedicines 2022;10:1480. [DOI: 10.3390/biomedicines10071480] [Reference Citation Analysis]
7 Narváez J, Díaz del Campo Fontecha P, Brito García N, Bonilla G, Aburto M, Castellví I, Cano-jiménez E, Mena-vázquez N, Nieto MA, Ortiz AM, Valenzuela C, Abad Hernández MÁ, Castrejón I, Correyero Plaza M, Francisco Hernández FM, Hernández Hernández MV, Rodríquez Portal JA. Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 2: tratamiento. Reumatología Clínica 2022. [DOI: 10.1016/j.reuma.2022.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen N, Diao C, Gao J, Zhao D. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: clinical features, biomarkers, and treatment options. Seminars in Arthritis and Rheumatism 2022. [DOI: 10.1016/j.semarthrit.2022.152004] [Reference Citation Analysis]
9 Mena-Vázquez N, Redondo-Rodríguez R, Rojas-Gimenez M, Romero-Barco CM, Manrique-Arija S, Ortega-Castro R, Hidalgo Conde A, Arnedo Díez de Los Ríos R, Cabrera César E, Espildora F, Aguilar-Hurtado MC, Añón-Oñate I, Pérez-Albaladejo L, Abarca-Costalago M, Ureña-Garnica I, Velloso-Feijoo ML, Irigoyen-Oyarzábal MV, Fernández-Nebro A. Efficacy and Safety of Rituximab in Autoimmune Disease-Associated Interstitial Lung Disease: A Prospective Cohort Study. J Clin Med 2022;11:927. [PMID: 35207203 DOI: 10.3390/jcm11040927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev 2022;:103056. [PMID: 35121155 DOI: 10.1016/j.autrev.2022.103056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
11 Mena-Vázquez N, Rojas-Gimenez M, Romero-Barco CM, Manrique-Arija S, Hidalgo Conde A, Arnedo Díez de Los Ríos R, Cabrera César E, Ortega-Castro R, Espildora F, Aguilar-Hurtado MC, Añón-Oñate I, Pérez-Albaladejo L, Abarca-Costalago M, Ureña-Garnica I, Velloso-Feijoo ML, Redondo-Rodriguez R, Fernández-Nebro A. Characteristics and Predictors of Progression Interstitial Lung Disease in Rheumatoid Arthritis Compared with Other Autoimmune Disease: A Retrospective Cohort Study. Diagnostics (Basel) 2021;11:1794. [PMID: 34679492 DOI: 10.3390/diagnostics11101794] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Vicente-Rabaneda EF, Serra López-Matencio JM, Ancochea J, Blanco R, González-Gay MÁ, Castañeda S. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opin Drug Saf 2021;:1-23. [PMID: 34433372 DOI: 10.1080/14740338.2021.1973428] [Reference Citation Analysis]
13 Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Castañeda S, González-Gay MÁ. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. Autoimmun Rev 2021;20:102830. [PMID: 33887489 DOI: 10.1016/j.autrev.2021.102830] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
14 Robles-pérez A, Molina-molina M, Narváez J. Tratamiento actual de la enfermedad pulmonar intersticial asociada a la artritis reumatoide. Open Respiratory Archives 2021;3:100106. [DOI: 10.1016/j.opresp.2021.100106] [Reference Citation Analysis]
15 Cronin O, McKnight O, Keir L, Ralston SH, Hirani N, Harris H. A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease. Rheumatol Int 2021;41:921-8. [PMID: 33721094 DOI: 10.1007/s00296-021-04835-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Narváez J, Otón T, Calvo-Alén J, Escudero-Contreras A, Muñoz-Fernández S, Rodríguez-Heredia JM, Romero-Yuste S, Vela-Casasempere P, Luján S, Baquero JL, Carmona L. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey. Joint Bone Spine 2021;88:105172. [PMID: 33689842 DOI: 10.1016/j.jbspin.2021.105172] [Reference Citation Analysis]
17 Mena-Vázquez N, Rojas-Gimenez M, Romero-Barco CM, Manrique-Arija S, Francisco E, Aguilar-Hurtado MC, Añón-Oñate I, Pérez-Albaladejo L, Ortega-Castro R, Godoy-Navarrete FJ, Ureña-Garnica I, Velloso-Feijoo ML, Redondo-Rodriguez R, Jimenez-Núñez FG, Panero Lamothe B, Padin-Martín MI, Fernández-Nebro A. Predictors of Progression and Mortality in Patients with Prevalent Rheumatoid Arthritis and Interstitial Lung Disease: A Prospective Cohort Study. J Clin Med 2021;10:874. [PMID: 33672699 DOI: 10.3390/jcm10040874] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
18 Immunosuppressants. Reactions Weekly 2020;1824:157-157. [DOI: 10.1007/s40278-020-84125-5] [Reference Citation Analysis]